Insider Brief
- Dash Bio has raised $11 million in new funding, bringing its total to $17.5 million, to accelerate its mission of transforming bioanalysis in drug development.
- Led by The Aligned Fund with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and others, the round supports Dash Bio’s efforts to automate and modernize bioanalysis workflows traditionally outsourced to slow, manual CROs.
- Dash Bio operates a GLP-compliant, highly automated lab that delivers key assays like ELISA, LC-MS, and qPCR up to 10x faster than traditional providers, aiming to reduce bottlenecks and speed biotech candidates from discovery to approval.
PRESS RELEASE — Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, today announced it has raised an additional $11 million in funding, bringing its total raised to $17.5 million. The new financing was led by The Aligned Fund, with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and others.
Dash Bio’s mission is bold but urgent: to rebuild drug development for a modern biotech era. While drug discovery has seen massive innovation through AI, mRNA, and CRISPR, drug development — the 7–12 year, multi-billion-dollar black hole between discovery and approval — remains stuck in a slow, expensive, and highly manual past. Over 70% of development work is outsourced to CROs whose labor-intensive service models are misaligned with the industry’s need for speed.
Dash Bio is tackling this bottleneck head-on. The company has built the first highly automated, GLP-compliant bioanalysis lab purpose-built to eliminate the friction of traditional CROs. Dash delivers assays like ELISA, LC-MS, and qPCR at speeds up to 10x faster than current providers — helping drug developers move from idea to IND to approval faster than ever before.
We founded Dash because the broken state of development is one of the biggest threats to progress in biotech.Dave Johnson, Dash Bio CEO
“We founded Dash because the broken state of development is one of the biggest threats to progress in biotech,” said Dave Johnson, co-founder and CEO of Dash Bio and former Chief Data & AI Officer at Moderna. “Our platform was designed the right way from day one: real automation, real integration, and real science. This funding is a strong signal that the industry is ready to embrace a new standard — one where bioanalysis is a catalyst, not a constraint.”
The company’s approach is resonating. Since its initial raise, Dash has added top-tier biopharma companies as customers and assembled a powerhouse team including former colleagues from Moderna, Science Exchange, Rootpath, and other trailblazers. With deep expertise in bioanalysis, software engineering, and lab automation, the team is uniquely positioned to bring industrial-grade efficiency to drug development.
“Dash Bio isn’t just faster — it’s foundational,” said Ariel Winton-Jones, Partner at The Aligned Fund. “Their team has built the kind of tech-forward infrastructure that biotech has needed for years. We believe Dash is creating the modern stack for bioanalysis and beyond.”
With this funding, Dash Bio will continue scaling its automated platform, expanding its assay menu, investing in its proprietary sample and assay management software, and onboarding new customers from preclinical through late-stage clinical development.
